Payment Terms and Reports. Royalties shall accrue and be payable by Licensee on a quarterly basis within forty five (45) days following the end of each calendar quarter in which any Sale of a Product or receipt of Sublicense Income occurs. Each payment of Royalties shall be accompanied by a statement setting forth in reasonable detail (i) with respect to Sales of Products, the number and each type of Product sold and the Gross Sales Price applicable thereto, (ii) with respect to Sales of Intellectual Property, the nature of the Sale and revenues applicable thereto, (iii) the party paying the Sublicense Income and the nature and amount of such income, and (iv) such additional details as may be reasonably requested by CSMC for the determination of Royalties payable hereunder. Except as otherwise provided in Paragraph 4(c) or (e) of this Schedule G, all Royalties shall be paid in United States dollars and shall be made without set off (except as expressly provided in Paragraph 6 below) and free and clear of (and without any deduction or withholding for) any taxes, duties, levies, imposts or similar fees or charges.
Payment Terms and Reports. Payments due under Section 2.2 shall be payable to PcoMed by Integra on a quarterly basis within 45 days following the end of each calendar quarter. Each such payment shall be accompanied by a statement setting forth in reasonable detail (i) the number and type of Treated Integra Product and Partially Treated Integra Product sold and the Net Sales applicable thereto, (ii) a breakdown of all the components of Net Sales for the determination of payments due under Sections 2.2 (the numbers may be and type of products may be stated in the aggregate and not by customer and are not required to be detailed by geographic area unless Fee rates are different in different geographic areas). Treated Integra Product and/or Partially Treated Integra Product shall be considered as being sold for the purpose of the calculation of payments due under Sections 2.2 when the payments for the Treated Integra Product and/or Partially Treated Integra Product are received by Integra or its Affiliates from a Third Party. All payments to be made under this Agreement shall be paid in United States dollars. Net Sales of Treated Integra Product and/or Partially Treated Integra Product and fees in currencies other than United States dollars shall be first determined in the currency of the country in which they are earned and shall be converted (for the purpose of calculation only) in accordance with generally accepted accounting principles for financial reporting in the United States.
Payment Terms and Reports. Royalties shall accrue and be payable on a quarterly basis within forty-five (45) days following the end of each calendar quarter in which any Sale of Royalty Bearing Products occurs. Each payment of Royalties shall be accompanied by a statement setting forth in reasonable detail (i) with respect to Sales of Royalty Bearing Products or Intellectual Property, the number and each type of Royalty Bearing Product sold and the Gross Sales Price applicable thereto, (ii) with respect to Sales of Intellectual Property, the nature of the Sale and revenues applicable thereto, and (iii) such additional details as may be reasonably requested by CSMC or UCLA for the determination of Royalties payable hereunder. Except as otherwise provided in Section 4(c), all Royalties shall be paid in United States dollars and shall be made without set off (except as expressly provided in Section 5 below) and free and clear of (and *** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. without any deduction or withholding for) any taxes, duties, levies, imposts or similar fees or charges.
Payment Terms and Reports. All amounts are payable in EUR (Euros) and shall become due in accordance with Annex COMMISION PLAN. With all such payments, BDA shall provide reports to GUEST detailing all amounts payable and the basis for the determination of such fees. Timely Payments. Failure to make payment of any undisputed amount by BDA when due hereunder, shall constitute a material breach of this Agreement. Taxes and Duties. BDA shall be solely responsible for and shall pay all taxes, duties, import deposits, assessments and other governmental charges, however designated, which are now or hereafter imposed by any governmental authority or agency that are based on (a) the payment of any amount by BDA to GUEST pursuant to this Agreement for the Licensed Software or (b) the import of the Products if such transaction is international in nature, provided that BDA shall not be responsible for paying any taxes on the income of GUEST. Resale Price. BDA shall sell the Licensed Software and / or the Products and related services at such minimum retail prices as set forth on Annex COMMISION PLAN. In witness whereof, the parties have signed this Agreement effective as of the effective date. BDA GUEST (iSystems Information Technologies SL) Name: Name Xxxxxxxx Xxxxxx
Payment Terms and Reports. Royalties on account of sales by Licensee shall accrue and be payable to CSMC by Licensee on a quarterly basis within […***…] following the end of each calendar quarter in which any Sale of a Product by Licensee occurs. Licensee shall use the standard royalty reporting form set forth in Schedule F hereto. Royalties on account of sales or payments made by a sublicensee shall accrue and be payable to CSMC by Licensee on a quarterly basis within […***…] following the end of the calendar quarter in which payment is received by Licensee from a sublicensee. Each payment of Royalties shall be accompanied by a statement setting forth in reasonable detail (i) with respect to Sales of Products, the number and each type of Product sold and the Gross Sales Price applicable thereto, (ii) with respect to Sales of Intellectual Property, the nature of the Sale and revenues applicable thereto, and (iii) such additional details as may be reasonably requested by CSMC for the determination of Royalties payable hereunder. The Products shall be considered as being sold for the purpose of the calculation of royalties under this Agreement when the Products have been invoiced. Except as otherwise provided in Paragraph 4(c) of this Schedule E, all Royalties shall be paid in United States dollars and shall be made without off set (except as expressly provided in Paragraph 5 below) and free and clear of (and without any deduction or withholding for) any taxes, duties, levies, imposts or similar fees or charges. *Confidential Treatment Requested
Payment Terms and Reports. Payments due under Sections 7.1 and 7.2 shall be payable to Phytogen by Conor on a quarterly basis within [*] days following the end of each calendar quarter with respect to any Net Sales of Conor Devices incorporating Product in such quarter. Each such payment shall be accompanied by a statement setting forth in reasonable detail (i) the number and type of Conor Device incorporating Product sold in each country and the Net Sales applicable thereto, (ii) a breakdown of all the components of Net Sales set forth in clauses (i)—(iv) as set forth in Section 1.19, and (iii) such additional details as may be reasonably requested by Phytogen for the determination of payments due under Sections 7.1 and 7.2. Conor Devices incorporating Product shall be considered as being sold for the purpose of the calculation of payments due under Section 7.1 and 7.2 when the payments for the Conor Device are earned and recorded by Conor or its Affiliates from a Third Party in accordance with GAAP. Except as provided in Section 7.3(c) below, all payments to be made under this Agreement shall be paid in United States dollars. Net Sales of Conor Devices and fees in currencies other than United States dollars shall be first determined in the currency of the country in which they are earned and shall be converted monthly into an amount in U.S. Dollars at the average of the bid and ask prices reported in the California edition of The Wall Street Journal as of the close of the last business day of such month in which such Net Sales are earned. All such converted Net Sales shall be consolidated with U.S. Net Sales for each calendar quarter and the applicable payments determined therefrom.
Payment Terms and Reports. KVP shall pay all amounts under Section 3.1 at least three (3) Business Days prior to the corresponding amount becoming payable to FemPharm under the applicable provision of the Acrux License. In addition, KVP shall provide all reports required to be provided to FemPharm (which reports shall meet all of the applicable requirements therefore as set forth in the Acrux License) with respect to such payments at least three (3) Business Days prior to the corresponding report becoming due to FemPharm under the applicable provision of the Acrux License including Section 4.7 of the Acrux License. It is understood that VIVUS shall have the right to provide a copy of all such reports to FemPharm under and in accordance with the Acrux License. *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. Notwithstanding the foregoing in lieu of payment of amounts to VIVUS hereunder, KVP may upon written notice to VIVUS elect to pay amounts otherwise due hereunder directly to FemPharm in accordance with the Acrux License, provided that and without limiting Section 9.7 KVP shall copy VIVUS on all correspondence and reports with respect thereto.
Payment Terms and Reports. With the exception of the sums being paid pursuant to Section 5.1(a) above, Ceridian shall pay to Ultimate all amounts due pursuant to Sections 5.1(b) and 5.2 for each calendar month within thirty (30) days after the end of such month. All amounts are payable in U.S dollars. With all such payments, Ceridian shall provide reports to Ultimate detailing all amounts payable and the basis for the determination of such amounts. 5.4
Payment Terms and Reports. 16.1 The Supplier shall issue (i) a proforma invoice for each Order on or at any time the Order is accepted by the Supplier; and (ii) the definitive invoice on or at any time after the Delivery Date (that is, once the Products are manufactured and delivered to the freight company appointed by the Distributor at the Delivery Location).
Payment Terms and Reports. Licensee shall make payments of royalties to Licensor on a quarterly basis with such payments to be made within thirty (30) days after the end of each fiscal quarter. Such payments shall be accompanied by a written statement summarizing the generation of such payments with the following information:
